Subscribe to our Email Alerts

ASX Announcements


 
    App 4D - Financial Report Half Year Ended 30 Sep 2019  
 
    App 4C - Sep 2019 Qtr Cash Flows Statement  
 
    Change of Director's Interest - Dr Robert Peach - Placement  
 
    Change of Director's Interest - Dr C Behrenbruch - Placement  
 
    Change of Director's Interest - Dr Warwick Tong, Placement  
 
    Placement Cleansing Notice  
 
    App 3B Placement Shares and Options to Directors and Mgt  
 
    Amplia Therapeutics Provides Manufacturing Update  
 
    Results of Annual General Meeting  
 
    Change of Director's Interest - S Wilkinson - Options Lapsed  
 
    Amplia Therapeutics - Quarterly Update  
 
    Change of Director's Interest - Dr Warwick Tong Rights Issue  
 
    Change of Director's Interest - Dr Chris Burns, Rights Issue  
 
    Change of Director's Interest - Andrew Cooke, Rights Issue  
 
    Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr  
 
    RightsIssue Participation Supports Clinical-Enabling Studies  
 
    Amplia Therapeutics - Bioshares Presentation July 2019  
 
    Appendix 4G - Key to Corporate Governance Disclosures  
 
    2019 Corporate Governance Statement  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to Shareholders - YE 31 March 2019  
 
    Amplia Therapeutics Reports Lead Candidate Preclinical Data  
 
    Amplia to present to Bioshares Biotech Summit  
 
    Update - July 2019 Newsletter  
 
    Letter to Shareholders - Rights Issue  
 
    Appendix 3B - Rights Issue  
 
    Rights Issue Prospectus  
 
    Financial Report Year Ended 31 March 2019  
 
    Dr John Lambert appointed as new CEO  
 
    Preliminary Rights Issue Details  
 
    Placement Cleansing Notice  
 
    Appendix 3B - Placement $360k  
 
    Capital Raising for Clinical-Enabling Studies  
 
    Preliminary Final Report - Year Ended 31 March 2019  
 
    Appendix 4C - Quarterly Statement of Cash Flows  
 
    European Patent Completes IP Protection in Major Markets  
 
    Amplia Expands Advisory Board  
 
    Update - February 2019 Newsletter  
 
    App 4D Half Year Accounts 30 Sep 2018  
 
    Change of Director's Interest - Wilkinson - Options Expired  
 
    Change of Director's Interest Notice - Andrew Cooke  
 
    Appendix 4C - quarterly  
 
    Amplia Investor Introduction  
 
    Change of Name to Amplia Therapeutics Limited - ATX  
 
    Change of Director's Interest - Cooke - Options  
 
    Change of Director's Interest - Peach - Options  
 
    Change of Director's Interest - Wilkinson - Options  
 
    Appendix 3B - Options